LOS ANGELES -- The novel agent soticlestat flopped in a pair of phase III trials for rare seizure disorders, researchers reported here. Among Dravet syndrome patients in the SKYLINE trial ...

Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show. The BECOME-TSC study evaluated outcomes of Epidiolex (Jazz ...

LOS ANGELES — A wearable, behind-the-ear EEG device is feasible for assessment of sleep patterns in young people with Dravet syndrome, according to a poster presented at the American Epilepsy ...

Dravet syndrome is a genetic developmental and epileptic ... clinical data demonstrating relutrigine’s ability to reduce seizure frequency and improve overall seizure control, highlighting ...

Pirates from across the country attended the funeral of a 14-year-old fan of all things swashbuckling. Billy Maskell, from ...

Daily seizures make it unsafe for her to be left ... of raising children with rare conditions. "My daughter has Dravet syndrome, she's 3, and I'm not sure what kind of life she will have.

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its ...

“What families and we as clinicians now want are medicines that go beyond reducing seizures to address the neurodevelopmental issues associated with Dravet syndrome, including giving patients ...

The diagnosis of Dravet syndrome was adjudicated independently by the Epilepsy Study Consortium. The study treatment period was 16 weeks including a 4-week titration period and 12 weeks ...

Praxis Precision Medicines, Inc. has announced that the U.S. FDA has granted Rare Pediatric Disease Designation for its drug relutrigine in treating Dravet syndrome, a severe genetic epilepsy ...